Stanford Brad L, Zondor Stacey D
School of Pharmacy, Texas Tech Health Sciences Center, Lubbock, TX, USA.
Ann Pharmacother. 2003 Dec;37(12):1825-30. doi: 10.1345/aph.1D262.
To review the pharmacology, pharmacokinetics, and place of bortezomib in the therapy of multiple myeloma (MM).
A MEDLINE search was conducted (1985-May 2003). Meeting abstracts, bibliographies from identified articles, and the package insert were also used. Search terms were bortezomib, multiple myeloma, Velcade, PS-341, LDP-341, MLNM341, and proteasome inhibitor.
All published information relevant to the clinical activity of bortezomib in MM was considered. All human clinical studies, with an emphasis on Phase II trials, were selected.
Current therapy for MM yields significant, although temporary, responses. Bortezomib is a novel anticancer agent with significant activity in relapsed and refractory MM.
Although the clinical trial data are incomplete, bortezomib offers a novel therapeutic modality for patients with MM who would otherwise have few options.
综述硼替佐米的药理学、药代动力学及其在多发性骨髓瘤（MM）治疗中的地位。
进行了MEDLINE检索（1985年至2003年5月）。还使用了会议摘要、已识别文章的参考文献以及药品说明书。检索词为硼替佐米、多发性骨髓瘤、万珂、PS - 341、LDP - 341、MLNM341和蛋白酶体抑制剂。
考虑了所有与硼替佐米在MM中的临床活性相关的已发表信息。选择了所有人体临床研究，重点是II期试验。
MM的当前治疗虽能产生显著但短暂的反应。硼替佐米是一种新型抗癌药物，在复发和难治性MM中具有显著活性。
尽管临床试验数据不完整，但硼替佐米为MM患者提供了一种新的治疗方式，否则这些患者的选择很少。
